<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 76 - Mims</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page75.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../index.html#p=76">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 76 - Mims</div>
        <div id="content-top2">P. 76</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../index.html#p=76"><img src="../thumb/76.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>66     TreaTmenT approaches
                                                                                                                                         curb appetite.                        1

            obesity revisited                                                                                                                                                        2-6
                                                                                                                                 feed determination.





                                                                                                               Endocrine Society Clinical Practice guideline on
          Dr GA Hough                             should recognise its disease status and alert their            pharmacological treatment of obesity 2015                7
          mbchb (UcT) Fcp(sa) cert endocrinology   obese patients to this. Studies found that patients
          & metabolism (sa)                       who received a formal diagnosis of overweight/        Pharmacotherapy should be              Weight loss medication is
          Specialist physician/endocrinologist /diabetologist   obesity from a healthcare provider, demonstrated   used as adjunct to behaviour   recommended for long-term weight
          in private practice, Port Elizabeth     a higher rate of positive dietary changes and/or      modification in patients with: 7       maintenance in patients with: 7
                                                  physical activity than patients whose condition                       2                                      2
                                                                   6,8
          obesity is one of the greatest medical challenges   remained undiagnosed.                     •  BMI ≥ 27 kg/m  with comorbidity     •  BMI ≥ 27 kg/m  with ≥ 1 comorbidity
          facing mankind today, with a rapidly accelerating   obesity is a complex and multifactorial disease   •  BMI &gt; 30 kg/m 2             •  BMI &gt; 30 kg/m 2
          prevalence in developing nations. 1     which results when energy intake in the form
            obesity reduces life expectancy – a direct   of food or drink exceeds energy expenditure.
          causal link between increased body-mass index   the excess energy is converted to fat, the most   Assessment of efficacy and         If a patient’s response to a weight loss


          and increased mortality has been established.  efficient and dense form of energy storage. excess   safety is recommended at least   medication is deemed effective (weight loss ≥
                                                                                                        monthly for the first 3 months, then at
                                                                                                                                               5 % of body weight at 3 months) and safe, we

            obesity is responsible for several other diseases,   fat is stored in different parts of the body, with   least every 3 months in all patients   recommend that the medication be continued 7
          including  type  2 diabetes mellitus which  is   the amount in each part being largely genetically   prescribed weight loss medications 7
          perhaps its most visible complication. other   determined. 9,10
          diseases and health risks include: 2,3,4,6
             C
            ardiovascular disease, namely hypertension,   diAgnose, clAssify And sTAge                In a survey of the American Society of Bariatric Physicians, 98 % treat obesity with
             coronary artery disease, cardiac failure and   the body-mass  index (bMI) remains the most             pharmacotherapy. Of those, 97 % prefer Phentermine 8
                                                                       5
             stroke                               widely used, simplest and most easily accessible
                                                                                    5,6
             M
            etabolic disorders, such as gout and   measure to assess weight and diagnose obesity
             hyperlipidaemia                      (see Figure 1).                                                                 Efficacy of phentermine: 9

            Chronic kidney disease                 according to the bMI classification, obesity is
             G
            allstones                            divided into three risk classes, associated with     •  Overall, phentermine-treated patients lost 12.1 % of their baseline body weight by week 12*
            nfertility                           increasing risks for both morbidity and mortality.   •  97 % of phentermine-treated patients lost ≥ 5 % of their baseline body weight by week 12*
             I
            ncreased cancer risk (breast, colorectal, pan-  a fourth level of bMI &gt;50 is usually called extreme
             I
             creatic, prostate, endometrial, oesophageal)  obesity, with Class three commonly referred to as   •  Phentermine successfully reduces body weight and food cravings
            obesity meets all the criteria for the definition   morbid obesity. 6

          of a disease  and is recognised  as such  by the   the reality is that obesity causes an increase in   •  36 % reduction in cravings in 12 weeks
          major healthcare authorities. 7,8   doctors, too,   mortality: each 5 kg/m  increase in bMI results in
                                                                   2
                                                                                                             • Efficacious and generally well tolerated • Shows significant weight loss
                                                                                                     • May be prescribed from the age of 12 years • Convenient and simple once-daily dosing
          figure 1. defining and classifying obesity
                                          5

                                                                                                                                          LET
                               definition and classification of obesity                               www.ilivelite.co.za              SCIENCE


                                                                                                                 program              HELP TAKE THE
              obesity is defined as abnormal or excessive fat   classifi cation  BMI (kg/m )                                          WEIGHT OFF

                                                                            2
               accumulation that may impair health
                                                   underweight      &lt;18.5                             COMMITTED TO RESULTS
              body mass index (bMI) provides the most   normal range   ≥18.5 and &lt;25
               convenient population-level measure of                                                *Studies were conducted on the HCl formulation
               overweight and obesity currently available  overweight  ≥25 and &lt;30                   Duromine is available as sustained action ion exchange resinate granules in capsules containing phentermine 15 mg or 30 mg. Duromine should be used in conjunction with an exercise, diet
                                                                                                     and behaviour modification program. Patients require medical review after a defined course of treatment, which ideally should not exceed 3 months.
                                                   obesity          ≥30                              References: 1. Duromine® approved package insert, July 2000. 2. Dellande S, Gilly MC, Graham JL. Gaining Compliance and Losing Weight: The Role of the Service Provider in Health Care
                                                                                                     Services. J Marketing 2004;68:78-91. 3. Elfhag K, Rössner S. Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight
                        weight (kg)                   obesity Class I  ≥30 and &lt;35                   regain. Obesity Rev 2005;6(1):67-85. 4. Mata J, Silva MN, Vieira PN, et al. Motivational “Spill-Over” During Weight. Control: Increased Self Determination and Exercise Intrinsic Motivation
                                                                                                     Predict Eating Self-Regulation. Health Psychol 2009;28(6):709-716. 5. Williams GC, Grow VM, Freedman ZR, et al. Motivational Predictors of Weight Loss and Weight-Loss Maintenance.
                    bmi =                                                                            J Pers Soc Psychol 1996;70(1):115-126. 6. Levy BT, Williamson PS. Patient Perceptions and Weight Loss of Obese Adults. J Fam Pract 1988;27(3):285-290. 7. Apovian CM, Aronne LJ,
                         height (m )                  obesity Class II  ≥35 and &lt;40                  Bessesen DH, et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015;100:342–362. 8. Hendricks EJ, Rothman RB,
                               2
                                                                                                     Greenway FL. How Physician Obesity Specialists Use Drugs to Treat Obesity. Obesity 2009;17:1730-1735. 9. Moldovan CP, Weldon AJ, Daher NS, Schneider LE, Bellinger DL, Berk LS, et al.
                                                      obesity Class III  ≥40                         Effects of a Meal Replacement System Alone or in Combination with Phentermine on Weight Loss and Food Cravings. Obesity 2016; 24: 2344-2350.
                                                                                                     Scheduling status:  S5  Proprietary name (and dosage form): Duromine 15 mg and 30 mg Capsules.  Composition: Sustained action
                                                                                                     ion-exchange resinate granules, available as capsules containing phentermine 15 mg and 30 mg Pharmacological classification:  A 11.3
                                                                                                     Anorexigenics. Indications: Duromine is an anorectic agent used in the management of obesity. Reference number: 15 mg: B657; 30 mg: B658
                                                                                                     [Act 101/1965]. Name and business address of applicant: iNova Pharmaceuticals (Pty) Limited. Co. Reg. No. 1952/001640/07, 15e Riley Road,
                                                                                                     Bedfordview. Tel. No. 011 087 0000. www.inovapharma.co.za. For full prescribing information, refer to the package insert as approved by the
          MIMS ConCISe GuIde to CardIovaSCular, MetabolIC and endoCrIne dISeaSeS  VOLUME 1           SAHPRA (South African Health Products Regulatory Authority). Further information is available on request from iNova Pharmaceuticals. IN3631/20</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page75.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page71.html">71</a>&nbsp;&nbsp;&nbsp;<a href="page72.html">72</a>&nbsp;&nbsp;&nbsp;<a href="page73.html">73</a>&nbsp;&nbsp;&nbsp;<a href="page74.html">74</a>&nbsp;&nbsp;&nbsp;<a href="page75.html">75</a>&nbsp;&nbsp;&nbsp;<a href="page76.html">76</a>&nbsp;&nbsp;&nbsp;<a href="page77.html">77</a>&nbsp;&nbsp;&nbsp;<a href="page78.html">78</a>&nbsp;&nbsp;&nbsp;<a href="page79.html">79</a>&nbsp;&nbsp;&nbsp;<a href="page80.html">80</a>&nbsp;&nbsp;&nbsp;<a href="page81.html">81</a>
             </td>
             <td width="35%"><a href="page77.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page77.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
